Amneal Insider Sale: 20% Share Drop Amid Exciting Lanreotide Launch and Strong Growth Outlook
Amneal insider sells 20k shares amid new lanreotide generic approval—insightful analysis of the company’s growth, investor impact, and pipeline prospects.
4 minutes to read